TAS-108: A Better Anti-Estrogen Drug for Treating Breast Cancer

Breast cancer, the most common cancer among women in the U.S., is often treated with the anti-estrogen therapies tamoxifen (TAM) and aromatase inhibitors (AIs). However, these drugs are not effective in all patients and can produce severe side effects, so there is a strong need for new hormonal therapies.

As a safer and more effective alternative to currently available drugs, SRI researchers have developed TAS-108, an oral anti-estrogen drug for the treatment of advanced breast cancer. This novel compound has completed a series of Phase I and Phase II clinical studies at multiple sites around the world.

Key benefits demonstrated in these studies include:

• Significant clinical antitumor efficacy in patients who have failed treatment with TAM and/or AI therapy

• No reduction in bone mineral density, a side effect seen with AIs

• No endometrial thickening, one of TAM's side effects

• An excellent overall safety profile

Learn more in the TAS-108 product summary.